A Phase 1 clinical trial that’s testing IMP761, an experimental treatment for multiple sclerosis (MS) and other autoimmune conditions, has dosed its first healthy participant, the therapy’s developer has announced.
Immutep received regulatory clearance to start the first-in-human trial of IMP761 in the Netherlands about a month ago. The study, which is expected to recruit 49 healthy adults at a single site in Leiden, will evaluate the therapy’s’s safety and pharmacological properties. Safety data are expected by year’s end, and information on its pharmacokinetics and pharmacodynamics by the first half of 2025. A therapy’s pharmacokinetics refers to its movement into, through, and out of the body, whereas pharmacodynamics describes a treatment’s effects on the body.
Read full story HERE….